Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 2a Study With an Extension Phase to Evaluate the Efficacy and Safety of BAY 3401016 in Participants Aged 18 to 45 With Alport Syndrome

NCT07211685 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT07211685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07211685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 2a Study With an Extension Phase to Evaluate the Efficacy and Safety of BAY 3401016 in Participants Aged 18 to 45 With Alport Syndrome
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 19, 2025
Completion date
November 29, 2027
Enrollment
60 (estimated)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome